Immunocore Holdings plc Operating Lease, Right-of-Use Asset, Amortization Expense
Immunocore Holdings plc (IMCR) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $1.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-06
- Immunocore Holdings plc operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $610.00K, a 7.39% increase year-over-year.
- Immunocore Holdings plc operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $627.00K, a 14.84% increase year-over-year.
- Immunocore Holdings plc operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $667.00K, a 19.11% increase year-over-year.
- Immunocore Holdings plc operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $567.00K, a 16.19% increase year-over-year.
- Immunocore Holdings plc operating lease, right-of-use asset, amortization expense for fiscal 2025 was $2.35M, a 22.80% increase from fiscal 2024.
- Immunocore Holdings plc operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.91M, a 16.09% increase from fiscal 2023.
- Immunocore Holdings plc operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.65M, a 20.66% decline from fiscal 2022.
- Immunocore Holdings plc operating lease, right-of-use asset, amortization expense for fiscal 2022 was $2.08M, a 0.00% change from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $610.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.24M 10-Q · filed 2026-08-06 | $1.90M derived: sum of 3 quarters · filed 2026-08-06 | $2.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $627.00K 10-Q · filed 2026-05-06 | $1.29M derived: sum of 2 quarters · filed 2026-05-06 | $1.86M derived: sum of 3 quarters · filed 2026-05-06 | $2.43M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $667.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.23M derived: sum of 2 quarters · filed 2026-02-25 | $1.80M derived: sum of 3 quarters · filed 2026-08-06 | $2.35M 10-K · filed 2026-02-25 |
| 2025-09-30 | $567.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.14M derived: sum of 2 quarters · filed 2026-08-06 | $1.68M 10-Q · filed 2025-11-06 | $2.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $568.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.11M 10-Q · filed 2026-08-06 | $1.67M derived: sum of 3 quarters · filed 2026-08-06 | $2.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $546.00K 10-Q · filed 2026-05-06 | $1.11M derived: sum of 2 quarters · filed 2026-05-06 | $1.59M derived: sum of 3 quarters · filed 2026-05-06 | $2.03M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $560.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.05M derived: sum of 2 quarters · filed 2026-02-25 | $1.48M derived: sum of 3 quarters · filed 2026-02-25 | $1.91M 10-K · filed 2026-02-25 |
| 2024-09-30 | $488.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $920.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.35M 10-Q · filed 2025-11-06 | $1.79M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $432.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $864.00K 10-Q · filed 2025-08-07 | $1.30M derived: sum of 3 quarters · filed 2026-02-25 | $1.70M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $432.00K 10-Q · filed 2025-05-07 | $869.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.27M derived: sum of 3 quarters · filed 2026-02-25 | $1.67M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $437.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $839.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.24M derived: sum of 3 quarters · filed 2026-02-25 | $1.65M 10-K · filed 2026-02-25 |
| 2023-09-30 | $402.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $803.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.21M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $401.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $808.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $407.00K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $2.08M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $2.08M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |